key: cord-0738682-ysfokbtd
authors: Vandergaast, R.; Carey, T.; Reiter, S.; Lathrum, C.; Lech, P.; Gnanadurai, C.; Haselton, M.; Buehler, J.; Narjari, R.; Schnebeck, L.; Roesler, A.; Sevola, K.; Suksanpaisan, L.; Bexon, A.; Naik, S.; Brunton, B.; Weaver, S. C.; Rafael, G.; Tran, S.; Baum, A.; Kyratsous, C. A.; Peng, K.-W.; Russell, S. J.
title: IMMUNO-COV™ v2.0: Development and Validation of a High-Throughput Clinical Assay for Measuring SARS-CoV-2-Neutralizing Antibody Titers
date: 2021-02-19
journal: nan
DOI: 10.1101/2021.02.16.21251653
sha: 757d8278c73a5293721c476cf8d4b4708f56e796
doc_id: 738682
cord_uid: ysfokbtd

Neutralizing antibodies are key determinants of protection from future infection, yet well-validated high-throughput assays for measuring titers of SARS-CoV-2-neutralizing antibodies are not generally available. Here we describe the development and validation of IMMUNO-COV v2.0 a scalable surrogate virus assay, which titrates antibodies that block infection of Vero-ACE2 cells by a luciferase-encoding vesicular stomatitis virus displaying SARS-CoV-2 spike glycoproteins (VSV-SARS2-Fluc). Antibody titers, calculated using a standard curve consisting of stepped concentrations of SARS-CoV-2 spike monoclonal antibody, correlated closely (p < 0.0001) with titers obtained from a gold-standard PRNT50% assay performed using a clinical isolate of SARS-CoV-2. IMMUNO-COV v2.0 was comprehensively validated using data acquired from 242 assay runs performed over seven days by five analysts, utilizing two separate virus lots, and 176 blood samples. Assay performance was acceptable for clinical use in human serum and plasma based on parameters including linearity, dynamic range, limit of blank and limit of detection, dilutional linearity and parallelism, precision, clinical agreement, matrix equivalence, clinical specificity and sensitivity, and robustness. Sufficient VSV-SARS2-Fluc virus reagent has been banked to test 5 million clinical samples. Notably, a significant drop in IMMUNO-COV v2.0 neutralizing antibody titers was observed over a six-month period in people recovered from SARS-CoV-2 infection. Together, our results demonstrate the feasibility and utility of IMMUNO-COV v2.0 for measuring SARS-CoV-2-neutralizing antibodies in vaccinated individuals and those recovering from natural infections. Such monitoring can be used to better understand what levels of neutralizing antibodies are required for protection from SARS-CoV-2, and what booster dosing schedules are needed to sustain vaccine-induced immunity.

virus stability relative to medium alone, though some matrix interference was observed at the 210 1:20 dilution. Thus, the IMMUNO-COV TM v2.0 assay is compatible with testing at low sample 211 dilutions, which may be of importance if higher detection sensitivities are desired.

Quantification of neutralizing antibody titers using a standard curve. To determine the titer 213 of neutralizing antibodies in a test sample without the need for serial two-fold sample dilutions, 214 we developed an assay format in which just one or two dilutions of a test sample are read against 215 a standard calibration curve included on every assay plate. For the development of a calibration 216 standard and assay controls, we used two well-characterized neutralizing anti-spike monoclonal 217 antibodies, mAb10914 and mAb10922. Both antibodies neutralized VSV-SARS2-Fluc in a dose-218 dependent manner (Fig. 6A ), whereas no virus inhibition was observed using isotype antibody at 219 any of the concentrations tested. Based on these findings we established a six-point standard 220 curve using two-fold dilutions of mAb10914 in tissue culture medium at concentrations ranging 221 from 0.8 µg/mL to 0.025 µg/mL (Fig. 6B) . To quantify the viral neutralizing titers of test 222 samples, each antibody concentration in the standard curve was converted to a virus neutralizing 223 titer (VNT) by multiplying the antibody concentration by 400. The correction factor of 400 was 224 chosen as it produced VNT values that approximated PRNT50% values obtained for samples 225 assayed at a 1:80 dilution (see below). The final standard curve range for the assay therefore 226 samples tested negative in IMMUNO-COV TM v2.0 (Table 2) . Assay sensitivity was 93.7% 256 relative to PRNT50% and 98.4% relative to PRNT80%. Moreover, 140 serum samples acquired 257 prior to March 2020 (134 acquired from 2017-2019, 5 acquired in early 2020) from donors 258 recovered from infection with endemic human coronaviruses HKU1 (n=35), NL63 (n=32), OC43 259 (n=35), or 229E (n=35) were all negative for neutralizing antibodies when tested using the 260 IMMUNO-COV TM v2.0 assay. Thus, the assay specifically detected neutralizing antibodies to 261 SARS-CoV-2 and most likely does not cross react to the four common human coronaviruses. 262 We also assessed assay variability. Each of the blinded serum samples was assayed on five with titers across five different runs exhibiting 27.9% CV (n=59), which compared favorably to a 267 CV of 65.1% for the PRNT (n=8 samples, two separate runs). Inter-assay precision was also 268 evaluated based on the performance of the standard curve and assay controls. For this purpose, 269 we included quality control (QC) high (0.154 µg/mL) and QC low (0.031 µg/mL) controls 270 consisting of mAb10922 spiked into negative pooled sera on each assay plate. From 207 assay 271 runs, QC high and QC low VNT readouts both demonstrated less than 30% inter-assay 272 variability (Table 3 and Fig. 7) . Intra-assay variability, which was assessed by running the same 273 controls in 24 wells of the same plate, was below 20% for both controls (QC high = 8.6%, QC 274 low = 19.1%). Collectively, these data demonstrate that the IMMUNO-COV TM v2.0 assay has 275 acceptably low levels of intra-and inter-assay variability.

Assay equivalence of serum and plasma samples. While most of our assay validation studies 277 were conducted using serum samples, we also performed matrix equivalency testing to confirm 278 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 19, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 assay compatibility with different plasma matrices. To this end, we acquired matched serum, 279 sodium heparin plasma, ACD plasma, and K2/EDTA plasma samples from 26 of the 176 280 subjects whose serum samples were used to evaluate assay specificity and sensitivity, and tested 281 the matched samples side-by-side in the assay. The consensus results and VNT antibody titers of 282 positive samples from five assay runs were compared for each matrix. The average percentage 283 relative error for each matrix was within ±30% for all plasma matrices ( antibodies. Therefore, we compared the titers (VNT) measured using IMMUNO-COV TM v2.0 291 with those determined by PRNT. A strong correlation (Pearson's R = 0.8870, p < 0.0001) was 292 observed between VNTs and PRNT50% titers (Fig. 8) . Therefore, neutralization of VSV-293 SARS2-Fluc in our assay closely mirrors the neutralization of SARS-CoV-2, and IMMUNO-294 COV TM v2.0 titers provide an accurate measure of an individual's level of neutralizing 295 antibodies. Moreover, VNTs can be quickly compared to PRNT50% titers using a conversion 296 table (Table 5) , which we generated based on our data obtained using the two different assays.

Individuals with more severe disease symptoms tend to develop higher titers of neutralizing 298 antibodies. Increasing evidence indicates that disease severity influences the strength of the 299 neutralizing antibody response (7, 8, 16, 28, 32) . To examine whether individuals in our study with 300 more severe disease developed higher titers of neutralizing antibodies, we correlated antibody 301 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 19, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 positive for SARS-CoV-2-neutralizing antibodies. Samples used for this analysis were collected 303 within the time window of two weeks to two months post confirmation of COVID-19 diagnosis.

A wide range of neutralizing antibody titers was observed among these donors with significant 305 overlap between the disease severity groupings (Fig. 9 ). Mean neutralizing antibody titers 306 increased with increasing disease severity, though differences were not statistically significant.

Our data, therefore, support previous findings that strong neutralizing antibody responses are 308 more likely in individuals who have recovered from severe disease, but wide variation in 309 neutralizing titers occur within all disease severity groupings. Table 6 ). The outlier showed a 3-fold increase, suggesting possible 320 asymptomatic re-exposure to the virus. In three subjects, the VNT from October dropped below 321 the limit of detection in serum, though neutralizing antibodies could still be detected at very low 322 levels in ACD-plasma from two of these subjects. Together, these data indicate that SARS-CoV-323 2 neutralizing antibody titers fall quite rapidly over time following natural infection. Importantly, 324 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 19, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 while the PRNT confirmed the substantial decrement in SARS-CoV-2-neutralizing antibody 325 titers over six months (Fig. 10B) , a similar trend was not observed using a "neutralization" assay 326 that measures binding of the spike RBD to immobilized ACE2 receptor ( Fig. 10C and Table 6) .

When samples were tested using this SARS-CoV-2-spike RBD binding assay, antibody levels in 328 several subjects were similar in April and October. This finding highlights the importance of 329 quantifying neutralizing antibodies by inhibition of live virus rather than relying on a surrogate 330 receptor binding assay. 331 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. With vaccine roll-out ongoing and critical questions still unanswered regarding the durability 333 of protective immune responses, the need for an accurate, scalable test that can quantitatively (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 19, 2021. ; https://doi.org/10.1101/2021.02.16.21251653 doi: medRxiv preprint detected by a reduction in luciferase activity compared to cells that have been infected in the is accurate and reproducible even between different virus lots (Fig. 4) . Moreover, during 425 validation testing, the IMMUNO-COV TM v2.0 assay exhibited favorable precision compared to 426 the PRNT, with acceptable levels of intra-and inter-assay variability (Table 3 ) and low run-to-427 run variability in quantitative VNT readouts. Therefore, we believe that IMMUNO-COV TM v2.0 428 will provide a useful and lasting standardized assay that can be used to normalize and harmonize 429 neutralizing antibody titers for consistent monitoring of neutralizing antibody levels over time 430 and in large study populations. 431 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Spearman's correlation analysis was conducted.

All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 620 We would like to thank all the participants in our clinical trial, without whose willingness to 621 donate blood we would not have been able to develop and validate this assay. We thank (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 19, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 19, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 

Statistical comparison of VNT relative to PRNT50% was performed using Spearman's rank order 904 correlation analysis as both datasets had a non-gaussian distribution (p < 0.0001). 905 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 19, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 

All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 19, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 

All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 19, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 19, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 

Efficacy and